A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

被引：0

作者：

G Descamps

P Gomez-Bougie

C Venot

P Moreau

R Bataille

M Amiot

机构：

[1] Centre de recherches en Cancérologie Nantes/Angers,Oncology Therapeutic Department

[2] INSERM,undefined

[3] UMR 892,undefined

[4] UFR Médecine et Techniques Médicales,undefined

[5] Université de Nantes,undefined

[6] Nantes Atlantique Universités,undefined

[7] Sanofi-Aventis,undefined

[8] 13 quai Jules Guesde,undefined

[9] UFR Médecine et techniques Médicales,undefined

[10] Université de Nantes,undefined

[11] Hématologie Clinique,undefined

[12] CHU de Nantes,undefined

来源：

British Journal of Cancer | 2009年 / 100卷

关键词：

multiple myeloma; IGF-1/IGF-1R; bortezomib; CD45; translocation (4,14);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45neg myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45neg Myeloma patients, particularly those with the most aggressive form, t(4,14).

引用

页码：366 / 369

页数：3